首页> 外文OA文献 >Immunotherapy With Rituximab (RITUXAN)/Interleukin 2 (IL-2) Following Autologous Peripheral Blood Stem Cell Transplant (ASCT) as Treatment for CD20 Positive Non-Hodgkin's Lymphoma

【2h】

Immunotherapy With Rituximab (RITUXAN)/Interleukin 2 (IL-2) Following Autologous Peripheral Blood Stem Cell Transplant (ASCT) as Treatment for CD20 Positive Non-Hodgkin's Lymphoma

机译：自体外周血干细胞移植（ASCT）后利妥昔单抗（RITUXAN）/白介素2（IL-2）免疫疗法治疗CD20阳性非霍奇金淋巴瘤

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Holmberg L.A.; Maloney D.G.; Bensinger W.I.;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma. [J] . Van Besien K, Mehra R, Wadehra N, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2004,第6期

机译：白细胞介素2培养的外周血干细胞和白细胞介素2的自体移植在复发或难治性非霍奇金淋巴瘤中的II期研究。
2. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation. [J] . Tsai D, Moore H, Hardy C, Bone marrow transplantation . 1999,第5期

机译：利妥昔单抗（抗CD20单克隆抗体）治疗用于大剂量治疗和自体外周血干细胞移植后的进行性中度非霍奇金淋巴瘤。
3. Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma. [J] . Hardingham JE, Kotasek D, Sage RE, Journal of Clinical Oncology . 1995,第5期

机译：自体外周血干细胞移植后分子标记阳性细胞对非霍奇金淋巴瘤的意义。
4. AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR THE TREATMENT OF CANINE LYMPHOMA [C] . Steven E. Suter Canadian Veterinary Medical Association Convention . 2009

机译：用于治疗犬淋巴瘤的自体外周血干细胞移植
5. Regulation of CD20 in rituximab-resistant cell lines (RRCL) and B-cell non-Hodgkin's lymphoma (B-NHL) [D] . Tsai, Ping-Chiao 2012

机译：CD20在利妥昔单抗耐药细胞系（RRCL）和B细胞非霍奇金淋巴瘤（B-NHL）中的调节
6. Phase I study of cellular therapy using ex vivo expanded natural killer cells from autologous peripheral blood mononuclear cells combined with rituximab-containing chemotherapy for relapsed CD20-positive malignant lymphoma patients [O] . Junji Tanaka, Norina Tanaka, Yan-Hua Wang, 2020

机译：使用自体外周血单核细胞的离体扩增天然杀伤细胞联合含利妥昔单抗的化疗对复发的CD20阳性恶性淋巴瘤患者进行细胞治疗的I期研究
7. Immunotherapy with rituximab/interleukin 2 (IL-2) following autologous peripheral blood stem cell transplant (ASCT) as treatment for CD20 positive non-hodgkin’s lymphoma [O] . Holmberg L.A., Maloney D., Gooley T., 2006

机译：自体外周血干细胞移植（ASCT）后使用利妥昔单抗/白介素2（IL-2）进行免疫治疗，以治疗CD20阳性非霍奇金淋巴瘤

Immunotherapy With Rituximab (RITUXAN)/Interleukin 2 (IL-2) Following Autologous Peripheral Blood Stem Cell Transplant (ASCT) as Treatment for CD20 Positive Non-Hodgkin's Lymphoma

著录项

相似文献

相关主题

期刊订阅